Evidence mapPaperPMID 15727730Full record

ReviewCurrent atherosclerosis reports2005

Remnant lipoproteins and atherosclerosis.

ThB Twickler, G M Dallinga-Thie, M J Chapman, J S Cohn

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Triglycerides and cardiovascular risk.Current cardiology reviews · 2009
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

ThB TwicklerLaboratory of Vascular Medicine, Bd277, ErasmusMC, PO Box 2040, 3000 CA Rotterdam, Netherlands. g.dallinga@erasmusmc.nl.
G M Dallinga-Thie
M J Chapman
J S Cohn

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A recently developed assay for quantification of remnant-like particle cholesterol has provided considerable evidence that reinforces the concept that elevated levels of plasma remnants are associated with increased cardiovascular disease in different populations and distinct patient groups. In this review, we provide a brief summary of the most recently published studies, emphasizing the clinical relevance of remnant analysis. We discuss recent evidence that sheds light on the mechanisms that may underlie the atherogenicity of remnant lipoproteins. Taken together, these data provide new insight into the significance of remnant lipoproteins in the onset and development of premature atherosclerosis.

Indexed as

BiomarkersCholesterolCoronary Artery DiseaseEndothelium, VascularHumansLipoproteinsPrognosisRisk FactorsTriglyceridesBiomarkersCholesterolLipoproteinsremnant-like particle cholesterolTriglycerides

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.